Developing predictive assays: The phenotypic screening “rule of 3”
Fabien Vincent(Pfizer (United States)), Paula M. Loria(Pfizer (United States)), Marko J. Pregel(Pfizer (United States)), Robert V. Stanton(Pfizer (United States)), Linda Kitching(Pfizer (United States)), Karl Nocka(Pfizer (United States)), Régis Doyonnas(Pfizer (United States)), Claire M. Steppan(Pfizer (United States)), A. Gilbert(Pfizer (United States)), Thomas Schroeter(Pfizer (United States)), Marie‐Claire Peakman(Pfizer (United States))
Cited by 202
Abstract
Phenotypic drug discovery approaches can positively affect the translation of preclinical findings to patients. However, not all phenotypic assays are created equal. A critical question then follows: What are the characteristics of the optimal assays? We analyze this question and propose three specific criteria related to the disease relevance of the assay-system, stimulus, and end point-to help design the most predictive phenotypic assays.